GlaxoSmithKline May Be Motivated By Scandal, But Changing Compensation Schemes For Docs And Sales Reps Is The Right Move

GlaxoSmithKline May Be Motivated by Scandal, but Changing Compensation Schemes for Docs and Sales Reps Is the Right Move

GlaxoSmithKline May Be Motivated By Scandal, But Changing Compensation Schemes For Docs And Sales Reps Is The Right Move
GSK’s decision to stop paying doctors to speak about their products and to change sales representative compensation so that it is not tied directly to prescription volume is seen by some as a desperate attempt to deflect attention from recent scandals, including a $ 3 billion settlement of fraud and abuse allegations in the United States and the ongoing bribery scandal in China. Prescription Drug Abuse – Yahoo News Search Results